Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIb open-label single-arm study of benralizumab for background medication reduction in severe eosinophilic asthma
CTR20240511Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of benralizumab in eosinophilic asthma (EA), sponsored by AstraZeneca. Started Feb 2024; status: active.
02
Drugs
benralizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on CTR20240511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240511.